

Application News

No. **L567**

High Performance Liquid Chromatography

Analysis of Sodium Chondroitin Sulfate by ELSD-LT III

Chondroitin sulfate, which is contained in a lot of tissues such as cells and cartilages is a kind of mucopolysaccharides. Chondroitin sulfate is often included in eye drops and supplements as sodium chondroitin sulfate (hereinafter called as SCS) due to its positive effect to corneal protection and improvement of joint pain. SCS cannot be detected by UV-VIS spectrophotometric (UV) detector, which is often used in HPLC because SCS has very limited UV absorption. Therefore, refractive index detector (hereinafter called as RID) or evaporative light scattering detector (hereinafter called as ELSD) is used to detect SCS. ELSD is a highly versatile detector because it can be used to detect almost all compounds except volatile ones. It provides reduced analysis time and improved sensitivity compared to those of analyses in which RID is used due to applicability to gradient elution. Therefore, ELSD is used in analyses of various substances such as sugars and lipids.

Here, SCS in eye drops was analyzed by NexeraTM series with ELSD-LT III as a detector.

K. Matsuoka, N. Iwata

Analysis of SCS in Standard Solution by ELSD

Table 1 shows the analytical conditions of SCS (Manufactured by Tokyo Chemical Industry Co., Ltd., CAS No. 9082-07-9) by ELSD. Fig. 1 shows the chromatogram of SCS standard solution. Here, SCS was analyzed using a non-porous ODS column, which is suitable for protein analysis with gradient elution followed by ELSD. Wide function, a new feature of ELSD-LT III, automatically optimizes a parameter that are related to sensitivity and a single method file can be used for data acquisition regardless of sample concentration, from low to high.

Table 1	Analy	vtical	Conditions	(FLSD)	
I able I	Allal	yucai	Contaitions		

System	: Nexera lite		
Mixer	: Mixer MR 20 μ L ^{*1}		
Column	: Imtakt Presto FF-C18		
Column	(150 mm x 4.6 mm l.D., 2 µm)		
Mobile Phase	: A) Water/Triethylamine/Acetic Acid=100:1.1:0.5		
MODIle Pliase	B) Acetonitrile		
Time a Dura anno an			
Time Program	$: B \text{ conc. 5\% } (0 \text{ min}) \rightarrow 55\% (7 \text{ min}) \rightarrow 5\% (7 \text{ min}) \rightarrow 5$		
_	100% (7.10 – 9 min) $\rightarrow 5\%$ (9.10 min - 18 min)		
Flow Rate	: 0.35 mL/min		
Column Temp.	: 35 ℃		
Injection Vol.	: 1 μL		
Vial	: LabTotal for LC 1.5 mL, Glass ^{*2}		
Detection	: ELSD-LT III		
	Gain : Wide		
	Filter : 4 sec		
	Drift Tube Temp. : 100 °C		
	Nebulizer Gas : N ₂		
	Gas Pressure : 350 kPa		
*1 P/N: 228-72652-4	1 、 *2 P/N: 227-34001-01		




Fig. 1 Chromatogram of SCS Standard Solution (1000 mg/L) (ELSD)

Linearity and Repeatability

Calibration curve of SCS was created using four different concentrations of 250, 500, 750, 1000 mg/L. The response of ELSD was plotted on double logarithmic axes because the logarithm of ELSD response is in proportion to the logarithm of concentration. Fig. 2 shows the calibration curve. Table 2 shows the repeatability. The repeatability was confirmed using repeated analyses at 250 mg/L. The calibration curve showed excellent linearity ,with r² of more than 0.9999. The repeatability of retention time and area also showed good results. The relative standard deviations (%RSD, n=6) were 0.11 about retention time and 2.08 about area.





Table 2 Repeatability (250 mg/L Standard Solution) (ELSD)

Compound	Retention Time (%RSD)	Area (%RSD)
Sodium Chondroitin Sulfate	0.11	2.08

Analysis of SCS in Eye Drops by ELSD

This Analysis was carried out under the same analytical conditions shown in Table 1. Eye drops were diluted 10 times with water and filtered with a 0.2 μ m membrane filter to analyze. Fig. 3 shows the chromatogram of the eye drops. The determination result of SCS in the ten time diluted eye drops was 629.4 mg/L. This value was calculated using the calibration curve in Fig. 2. It is strongly recommended that the ingredient SCS of the sample was used for creating the calibration curve due to the difference of molecular weight distribution over every production lot of SCS.



Analysis of SCS in Eye Drops by RID

Table 3 shows the analytical conditions of SCS in eye drops by RID. A water-based SEC (GFC) column was used to analyze SCS. 50 μ L was injected in order to certainly detect the SCS peak. The pretreatment of eye drops was the same as described above. Fig. 4 shows the chromatogram. Components of the eye drops were not able to be separated because gradient elution was impossible to be applied to RID is used due to its character. On the other hand, the analysis by ELSD has advantages, for example excellent separation, shorter analysis time, and good sensitivity so on, because gradient elution can be applied .

Table 3 Analytical conditions (RID)				
System	: Nexera lite			
Mixer	: Mixer MR 180 µLll ^{*1}			
Column	: Shodex OHpak SB-806M HQ			
	(300 mm x 8.0 mm I.D.,13 µ m)			
Mobile Phase	: 50 mmol/L Sodium Sulfate aq. : Methanol=95 : 5			
Flow Rate	: 1.0 mL/min			
Column Temp.	: 40 °C			
Injection Vol.	: 50 µL			
Vial	: LabTotal for LC 1.5 mL, Glass ^{*2}			
Detection	: RID-20A			
	Polarity : +			
	Cell Temp. : 40 °C			
	Response : 1.5 sec			
	-			

^{*1} P/N: 228-72652-44、 *2 P/N: 227-34001-01




Fig. 4 Chromatogram of eye drops (diluted 10 times) (RID)

Conclusion

Analysis of SCS in eye drops were carried out. In this article, a non-porous ODS column was used for separation and ELSD-LT III was used as a detector. In the analysis in which ELSD was used, use of gradient elution afforded to the separation the components of the eye drops and the determination of SCS.

Wide function, a new feature of ELSD-LT III, automatically optimized a parameter that were related to sensitivity and a single method file were able to be used for data acquisition regardless of sample concentration, from low to high.

Nexera is a trademark of Shimadzu Corporation in Japan and/or other countries.

OHpak is a trademark or a registered trademark of SHOWA DENKO K.K.

Third-party trademarks and trade names may be used in this publication to refer to either the entities or their products/services, whether or not they are used with trademark symbol "TM" or "®".



For Research Use Only. Not for use in diagnostic procedure

This publication may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. Shimadzu disclaims any proprietary interest in trademarks and trade names used in this publication other than its own. See http://www.shimadzu.com/about/trademarks/index.html for details.

The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.

First Edition: Sep. 2020

Shimadzu Corporation www.shimadzu.com/an/